In Phase I/II trials, perifosine has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. Perifosine has shown single agent partial responses or long term disease stabilizations in solid tumors including, renal, hepatocellular, sarcoma and prostate cancer. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Responding patients, including those with stable disease, have been treated for months to more than three years.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition,
development and commercialization of medically important, novel
pharmaceutical products for the treatment of life-threatening
diseases, including diabetes and cancer. Keryx's lead compound
under development is Sulonex(TM) (sulodexide oral gelcap),
previously referred to as KRX-101, a first-in-class, oral
heparinoid compound for the treatment of diabetic nephropathy, a
life-threatening kidney disease caused by diabetes. Sulonex is in a
pivotal Phase III and Phase IV clinical program under a Special
Protocol Assessment with the Food & Drug Administration.
Additionally, Keryx is developing Zerenex(TM), an oral, inorganic,
iron-based compound that has the capacity to bind phosphate and
form non-absorbable complexes. Zerenex is currently in Phase II
clinical development for the treatment of hyperphosphatemia
(elevated serum phosphorous levels) in patients with end- stage
renal disease. Keryx is also developing clinical-stage oncology
compounds, including KRX-0401, a novel, first-in- class, oral
modulator of Akt, a pathway associated with tumor survival and
growth, and other important signal transduction pathways. KRX-0401
is currently in Phase II clinical development for multiple tumor
types. Keryx also has an active in-licensing and acquisit